Dendreon Plunges on Provenge Revenue Forecast Withdrawal
1,538 views · Published 4 August 2011 · 2:45 · Indexed 30 October 2026
Channel: Bloomberg Originals · 2011 · Entertainment
Aug. 4 (Bloomberg) -- Dendreon Corp., maker of the prostate-cancer drug Provenge, fell the most in two years after the company withdrew its 2011 revenue estimate and said sales of the medicine didn't meet projections. Shannon Pettypiece reports on Bloomberg Television's "In the Loop." (Source: Bloomberg)
More from this channel
-
3:30
Market Close 6.4 - Bloomberg
-
0:17
Pens Tie Stanley Cup Series - Bloomberg
-
0:35
Hardware Price Too High - Activision - Bloomberg
-
0:31
FDIC Seeks Citigroup Shares-Up - WSJ - Bloomberg
-
0:44
Bank Have More Accounting Leeway - Bloomberg
-
0:32
Lakers Beat Magic 100-75 - Bloomberg
-
0:30
Johnson Wins 300th Game - Bloomberg
-
1:13
GM Expects To Sell Saturn To Penske Automotive - Bloomberg